Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4005 EUR | +1.39% | +1.39% | -12.93% |
May. 07 | GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding | CI |
Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
Sales 2024 * | 4.4M 4.74M | Sales 2025 * | 7.4M 7.97M | Capitalization | 31.25M 33.67M |
---|---|---|---|---|---|
Net income 2024 * | -26M -28.02M | Net income 2025 * | -25M -26.94M | EV / Sales 2024 * | 20.2 x |
Net Debt 2024 * | 57.8M 62.28M | Net Debt 2025 * | 85.7M 92.34M | EV / Sales 2025 * | 15.8 x |
P/E ratio 2024 * |
-0.7
x | P/E ratio 2025 * |
-0.72
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.4% |
1 day | +1.39% | ||
1 week | +1.39% | ||
Current month | +1.39% | ||
1 month | -1.23% | ||
3 months | +10.03% | ||
6 months | -33.25% | ||
Current year | -12.93% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 21-05-18 | |
Scott Jeffers
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Magali Taiel
CTO | Chief Tech/Sci/R&D Officer | - | 18-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 13-09-30 |
Cédric Moreau
BRD | Director/Board Member | 37 | 19-06-10 |
Maritza McIntyre
BRD | Director/Board Member | 58 | 19-06-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 0.4005 | +1.39% | 239,142 |
24-05-08 | 0.395 | +0.64% | 73,868 |
24-05-07 | 0.3925 | -0.63% | 539,173 |
24-05-06 | 0.395 | 0.00% | 0 |
24-05-03 | 0.395 | 0.00% | 0 |
Real-time Euronext Paris, May 09, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.93% | 33.12M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- SIGHT Stock